Advertisement
Advertisement
U.S. markets close in 4 hours 17 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Avivagen Inc. (VIVXF)

Other OTC - Other OTC Delayed Price. Currency in USD
0.06170.0000 (0.00%)
As of 12:43PM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0617
Open0.0616
BidN/A x N/A
AskN/A x N/A
Day's Range0.0617 - 0.0617
52 Week Range0.0540 - 0.2572
Volume13,900
Avg. Volume2,030
Market Cap5.631M
Beta (5Y Monthly)0.69
PE Ratio (TTM)N/A
EPS (TTM)-0.0770
Earnings DateJan 17, 2023 - Jan 23, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for VIVXF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • AVIVAGEN INC
    Daily – Vickers Top Buyers & Sellers for 12/05/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • Business Wire

    Avivagen Inc. Announces Closing of Second Tranche of a Private Placement of Shares

    OTTAWA, Ontario, October 31, 2022--Avivagen Inc. (TSXV:VIV) ("Avivagen" or the "Company"), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, announces that it has closed the second tranche (the "Second Tranche") of its previously announced non-brokered private placement financing (the "Offering") through the issuan

  • Business Wire

    Avivagen Inc. Announces Closing of First Tranche of a Non-Brokered Private Placement of Shares for Proceeds of up to $1.0 Million

    OTTAWA, Ontario, October 21, 2022--Avivagen Inc. (TSXV:VIV) ("Avivagen" or the "Company"), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, announces that it has closed the first tranche (the "First Tranche") of a non-brokered private placement financing of up to $1,000,000 (the "Offering") through the issuance of

  • Business Wire

    Avivagen Inc. Announces Proposed Non-Brokered Private Placement of Common Shares for Proceeds of up to $1.0 Million

    OTTAWA, Ontario, October 14, 2022--Avivagen Inc. (TSXV:VIV) ("Avivagen" or the "Company"), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, is announcing a proposed non-brokered private placement of its common shares (the "Shares") at a price of $0.20 per Share (the "Offering") for gross proceeds of up to $1,000,0

Advertisement
Advertisement